Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H1 2016

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H1 2016
Published Jun 28, 2016
58 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H1 2016, provides in depth analysis on Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2)
- The report reviews Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2)
- I

  
Source:
Document ID
GMDHC0121TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Overview71
Therapeutics Development83
  Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Products under Development by Stage of Development81
  Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Products under Development by Therapy Area91
  Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Products under Development by Indication101
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Products under Development by Companies132
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Products under Development by Universities/Institutes152
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Therapeutics Assessment177
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action182
  Assessment by Route of Administration202
  Assessment by Molecule Type222
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Companies Involved in Therapeutics Development246
  Alkermes Plc241
  Biomar Microbial Technologies251
  Cyxone AB261
  OncBioMune Pharmaceuticals Inc.271
  Transgene SA281
  ZIOPHARM Oncology, Inc.291
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Drug Profiles3012
  ALKS-4230 Drug Profile301
  Biologic to Activate IL-2 for Graft Versus Host Disease Drug Profile311
  BNZ-1321 Drug Profile321
  IB-08C175 Drug Profile331
  Monoclonal Antibody to Inhibit IL-2 and IL-15 for Oncology, Central Nervous System and Gastrointestinal Disorders Drug Profile341
  Prostatac Drug Profile352
  T-20K Drug Profile371
  TG-4010 Drug Profile384
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Dormant Projects423
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Discontinued Products451
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Featured News &Press Releases4611
  May 25, 2016: Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230461
  May 18, 2016: Doctors Voice Optimism About Phase 2 Trial of ProscaVax in Mexico for Prostate Cancer461
  May 11, 2016: OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer471
  May 04, 2016: OncBioMune Submits Protocol to Principal Investigators for Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer481
  Apr 28, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in China491
  Apr 12, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Hong Kong491
  Mar 29, 2016: Multiple sclerosis: plant peptide could prevent onset of the disease501
  Mar 16, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Europe511
  Feb 23, 2016: OncBioMune Continuing Phase 1 Trial, While Initiating Phase 2 Trial of ProscaVax for Prostate Cancer521
  Feb 10, 2016: Christian Gruber is "Inventor of the Year 2015" of MedUni Wien531
  Dec 23, 2015: Transgene Announces Publication in The Lancet Oncology of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer541
  Nov 10, 2015: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in China and Ukraine541
  Sep 08, 2015: Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer551
  Aug 19, 2015: Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer551
  Jun 01, 2015: Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer561
Appendix572
  Methodology571
  Coverage571
  Secondary Research571
  Primary Research571
  Expert Panel Validation571
  Contact Us571
  Disclaimer581

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Interleukin-2-T-Cell-Growth-Factor-or-Aldesleukin-or-IL2-Pipeline-Review-H1-2016-2088-16034>
  
APA:
Global Markets Direct - Market Research. (2016). Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Interleukin-2-T-Cell-Growth-Factor-or-Aldesleukin-or-IL2-Pipeline-Review-H1-2016-2088-16034>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.